



## Antibiotics Research in Canada

Guest Editors:

**Prof. Dr. Raymond J. Turner**

Department of Biological  
Sciences, University of Calgary,  
Calgary, AB T2N 1N4, Canada

**Prof. Dr. Roger C Levesque**

Microbiologie Médecine FRQS  
Chercheur Boursier Mérite  
Exceptionnel, Institut de Biologie  
Intégrative et des Systèmes  
(IBIS), Université Laval, Québec,  
QC G1K 7P4, Canada

Deadline for manuscript  
submissions:

**closed (31 December 2022)**

### Message from the Guest Editors

Dear Colleagues,

We would like to invite you to contribute a manuscript to a Special Issue focusing on Canadian Research efforts in the area of Antibiotics. As Canadian researchers, we are part of a strong history of contributions to the field of novel antibiotic developments and studying the resistance/tolerance/sensitivity processes. Canadian research in this area is broad, ranging from an academic interest in fundamental microbiology to the development of novel antimicrobials and bench-to-bed clinical research. With the understanding of antibiotic misuse in medicine and various industries, we all recognize that we are entering the post-antibiotic era and are well within the AMR era. The Antimicrobial Resistance initiative from the Canadian Institutes of Health Research within the Infection and Immunity Institute, international Joint initiatives, and our National Laboratory have provided many Canadian scientists with the ability to conduct novel and internationally competitive work. Recent cross-Canada projects considering a One Health approach to prevent or reduce the development and transmission of AMR are helping direct public outreach education and policies.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

## Contact Us

---

*Antibiotics* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
www.mdpi.com

mdpi.com/journal/antibiotics  
antibiotics@mdpi.com  
X@antibioticsmdpi